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Purpose: There is a dearth of research regarding the prevalence and nature of patient- 
reported rhinitis and its relationship with risk of asthma exacerbations. The aim of this study 
was to (i) determine the prevalence, severity and treatment of self-reported rhinitis symptoms 
among adults aged ≥18 years with asthma treated at Global Initiative for Asthma (GINA) 
Step 3 and above and (ii) compare the demographics, clinical characteristics, medication use, 
side-effects and healthcare practitioner review between patients who report rhinitis symp-
toms and those who do not and (iii) determine whether patient-reported rhinitis is associated 
with risk of asthma exacerbations in the total patient sample.
Patients and Methods: This analysis used data from the iHARP (Initiative Helping 
Asthma in Real-life Patients) asthma review service – a cross-sectional observational study 
(2011 and 2014) in seven countries that captured data on patient demographics, rhinitis 
symptoms, asthma symptoms, indicators of exacerbations, medication use, oropharyngeal 
effects and side-effects, using practitioner- and patient-reported questionnaires. Comparisons 
between patients with and without rhinitis were tested. Univariate logistic regression was 
used to identify variables associated with risk of exacerbations for entry into multivariable 
logistic regression.
Results: This report contains data from 4274 patients: 67.4% (2881/4274) reported rhinitis 
symptoms and of which 65.7% (1894/2881) had not received a doctor diagnosis; 36.5% 
(1052/2881) had moderate-severe rhinitis, 12.4% (358/2881) had used intranasal corticoster-
oids and 19.8% (569/2881) oral antihistamines. Patients with coexisting moderate-severe 
rhinitis were more likely to have GINA-defined uncontrolled asthma than those with mild 
rhinitis or no rhinitis. Moderate-severe rhinitis was associated with 40% increased risk of 
asthma exacerbations (OR=1.40, 95% CI: 1.02–1.90).
Conclusion: This study identified a major gap in the diagnosis and management of rhinitis 
in a cohort of people with asthma treated at GINA Step 3 and above who are managed in 
general practice. It highlights the need for practitioners to identify, evaluate and optimally 
treat rhinitis in adults with asthma, which is a significant factor associated with exacerbation 
risk.
Keywords: asthma symptom control, comorbidities, oral steroids, preventer, reliever, side- 
effects
Introduction
Asthma and rhinitis are both heterogenous chronic respiratory conditions, with 
prevalence rates increasing worldwide.1,2 Asthma affects ~30 million people in 
Europe1 and over 5 million people in the United Kingdom,3 with allergic rhinitis 
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(AR), the most common form of non-infectious rhinitis, 
affecting up to 32% of people in Europe and 29% of 
people in the United Kingdom.2,4 If uncontrolled, AR 
has a substantial negative impact on peoples’ lives, impos-
ing a high socioeconomic and health burden on individuals 
and society.5–9 Asthma and AR frequently coexist,10 with 
up to 80% of asthma patients having AR and over 40% of 
AR patients having asthma.11 The links between asthma 
and AR have been well characterised,12 and can be 
regarded as manifestations of a single syndrome in two 
contiguous parts of the respiratory tract.10 Both diseases 
share similar triggers and pathophysiology.4 AR usually 
precedes asthma and is an independent risk factor for the 
subsequent development of asthma.13–15
Beyond the symptomatic burden of uncontrolled rhini-
tis in asthma patients, significant uncontrolled rhinitis is a 
major trigger of asthma symptoms16 and predictor of poor 
asthma control,17–21 which in turn is a risk factor for 
exacerbations,16 thereby further compounding its impact 
and socioeconomic burden.18–24 In patients with asthma 
across various healthcare settings, the presence of uncon-
trolled rhinitis is associated with reduced asthma-related 
quality of life (QOL)18–22 and productivity,23 more physi-
cal limitations21,22 asthma medication use,20,23,24 increased 
rate of asthma-related general practitioner visits,23–25 
absences from work,23 emergency department visits24,25 
and hospitalisations24 compared to those without rhinitis. 
Furthermore, asthma patients with more severe rhinitis 
have worse asthma control than those with mild disease,17 
and an elevated risk of hospital readmission due to 
asthma.26
The Allergic Rhinitis and its Impact on Asthma 
(ARIA) guidelines highlight the importance of the link 
between asthma and AR, and suggest that patients with 
asthma are assessed for AR, and vice versa, so that man-
agement of symptoms can be optimised.4 Despite a global 
strategy for asthma management16 and evidence-based 
guidelines for AR management,4 recommendations are 
not fully applied in clinical practice.27–29 From the physi-
cian’s perspective, establishing a diagnosis of AR is 
becoming more demanding,12, and AR management is 
often difficult due to polysensitisation,30 the presence of 
both allergic and non-allergic disease elements (ie, mixed 
rhinitis)31 and entangling by phenotypes such as severe 
chronic upper airways disease.32 From the patient’s per-
spective, AR symptoms are often trivialised,33,34 and man-
agement is less than ideal due to the high level of self- 
diagnosis, self-selection of medication, and subsequent 
suboptimal or inappropriate self-management of rhinitis.-
34–38 This has far-reaching ramifications for patients with 
asthma, and adds to the need of ensuring that these indi-
viduals are identified, diagnosed and treated appropriately. 
While patients are known to trivialise AR symptoms, it 
appears that healthcare professionals (HCPs) might also 
trivialise and under-recognise this condition in patients 
with poorly controlled asthma, which may lead to 
untreated rhinitis and overtreatment of asthma;8,37–40 
thus, highlighting the importance of this study in primary 
care where most asthma in managed.
This study was developed in order to provide more 
data on the burden of rhinitis in asthma patients seen in 
general practice as there is a dearth of research regarding 
the prevalence and nature of patient-reported rhinitis and 
its relationship with the risk of exacerbations. We hypothe-
sised that the majority of self-reported rhinitis among 
primary care patients with a doctor diagnosis of asthma 
is undiagnosed as previously described,39,40 and that sig-
nificant rhinitis is associated with risk of asthma exacer-
bations. This research aimed to use the iHARP (initiative 
Helping Asthma in Real-life Patients) database41 to 
achieve the study objectives which were to (i) determine 
the prevalence, severity and treatment of self-reported 
rhinitis symptoms among adults aged ≥18 years with 
asthma treated at Global Initiative for Asthma (GINA) 
Step 3 and above and (ii) compare the demographics, 
clinical characteristics, medication-taking behaviours and 
HCP review by between patients who report rhinitis symp-
toms and those who do not and (iii) determine whether 
patient-reported rhinitis is associated with risk of asthma 
exacerbations in the total sample.
Methods
Data Source
This research used the iHARP database, an international 
database containing anonymised patient data obtained 
from practices receiving the iHARP asthma review 
service.41 Data were collected prospectively between 
June 2011 until December 2014 from enrolled primary 
care practices in Australia and 7 European countries 
(United Kingdom (UK), Italy, Spain, France, the 
Netherlands, Norway and Sweden).
Ethics approval for this asthma review service was 
acquired from each participating site according to coun-
try-specific requirements. In the UK, data were collected 
as part of quality improvement and became part of the 
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clinical record, whereas participants in all other countries 
provided signed informed consent. This cross-sectional 
observational study was registered with the European 
Network of Centres for Pharmacoepidemiology and 
Pharmacovigilance (ENCEPP) (as ENCePP/SDPP/9651).
Inclusion and Exclusion Criteria
Patients had to meet the following inclusion criteria for the 
asthma review service: they had to be 16 years and older, 
have a current diagnosis of asthma and were prescribed at 
least 12 months of fixed-dose combination inhaled corti-
costeroid and long-acting beta2 agonist therapy (ie, two 
prescriptions of GINA Step 3 or above therapy) in the year 
before the review. Patients were excluded if they had 
a diagnosis of any other chronic respiratory disease other 
than asthma, or they had received oral corticosteroids and/ 
or antibiotics for a lower respiratory condition in the 
2 weeks before the review, or they had received mainte-
nance systemic therapy for asthma. These exclusions were 
specified to minimise confounding on disease stability and 
control by additional treatments. The study cohort from 
the iHARP database for the current analysis was limited to 
adult patients (≥18 years old) who were from practices in 
the above 7 European countries.
Study Data and Assessments
In the iHARP asthma review, comprehensive information 
about patients’ demographics, asthma symptoms, rhinitis 
symptoms, inhaler technique, medication use, side-effects, 
occurrence of exacerbations and HCP review were col-
lected using practitioner-led and questionnaire-led assess-
ments. The questionnaire that was used is available in 
publications listed on the iHARP website41 and included 
the following sections:
Rhinitis symptoms were assessed using a single ques-
tion based on the ARIA and International Primary Care 
Respiratory Group definition of rhinitis;4,42 ‘Do you have 
any of these symptoms: itchy, runny, blocked nose or 
sneezing when you don”t have a cold?’, with responses 
ranging from, 0 (“no”), 1 (“occasionally and little 
bother”), 2“occasionally but quite a bother”), 3 (“most 
days but little bother”), or 4 (“most days and a lot of 
bother”). Patients were classified as having mild rhinitis 
if their responses were ‘1ʹ or ‘3ʹ and as having moderate- 
severe rhinitis if their responses were ‘2’ or ‘4’. Patient- 
reported intranasal corticosteroid (INCS) and/or oral anti-
histamine use for the treatment of rhinitis in the past year 
were also recorded.
The GINA criteria at the time were used to assess the 
level of asthma control during the week before the review 
visit.43 Patients were asked if they experienced: daytime 
symptoms (more than twice/week); any night wakening 
due to asthma; need for short-acting β-agonist (SABA) 
reliever (more than twice/week) and any limitation in day-
time activity. The level of asthma control was defined as 
controlled (none of the above), as partially controlled (1 or 
2 of the above) or as uncontrolled (3 or 4 of the above). 
Patients were also asked to rate their level of asthma 
control in response to the question; “In the past 4 weeks, 
did you believe that your asthma was ‘well controlled’?” 
with “yes” or “no” response options.
Adherence to asthma preventer therapy was assessed 
with a single question from the REALISE (Recognise 
Asthma and Link to Symptoms and Experience) study,44,45 
asking patients to choose a statement that best described 
how they take their preventer asthma medication. Patients 
were also asked to indicate the highest number of puffs of 
SABA reliever taken in one day during the previous 4 
weeks with ‘0–4’ or “5–12 or more” response options.
Patients were asked whether their inhaler technique 
had been checked by a HCP in the past year and whether 
they had seen a respiratory specialist for asthma outside 
the practice with response options “in the previous year”, 
“more than a year ago” or “never”. Patient-reported oro-
pharyngeal effects while inhaling preventer treatment (ie, 
feeling a sensation at the back of the throat, a need to 
cough and/or of medication being deposited at the back of 
the throat) and side-effects from preventer asthma medica-
tion (ie, continual sore mouth/throat, oral thrush, bruising, 
hoarse voice, cough and abnormal weight gain) were 
recorded during the review.
Patients reported whether they had experienced any 
asthma exacerbations in the previous 12 months before the 
review visit. Exacerbations were identified by one of the 
following events: (a) hospital admission with breathing or 
chest problems; (b) emergency department (ED) visit due to 
asthma; or (c) a short burst (5–10 days) of oral corticoster-
oids for worsening asthma. The total number of exacerba-
tions in the previous year (ie, a+ b+ c) were calculated for 
each patient; a total score of zero = no risk of exacerbations, 
and a total score ≥1 = yes risk of exacerbations.
Data Analysis
Statistical analyses were performed using SPSS (IBM® 
SPSS® Statistics) Version 24. There were two parts to 
the statistical analysis plan:
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Part 1: Descriptive statistics were used to summarise 
sample characteristics. Demographics, clinical characteris-
tics, behaviours regarding medication use and review by 
HCPs of patients who reported rhinitis symptoms were 
compared to those that did not. Normally distributed con-
tinuous variables such as age were compared using 
Student’s t-test, and for categorical variables such as gen-
der and smoking status the Pearson chi-square test was 
used.
Part 2: An exploratory analysis was performed to 
identify variables associated with risk of exacerbations 
among the total patient sample using univariable logistic 
regression models, where the risk of exacerbations (no/ 
yes) was the dependent variable and patient demo-
graphics, clinical characteristics, behaviours regarding 
medication use and HCP review were the predictor vari-
ables. Tolerance values were used to test for intercorrela-
tions among predictor variables, and those with high 
intercorrelations were not included for further analysis. 
Predictor variables that were significantly associated with 
risk of exacerbations were then entered into a multivari-
able logistic regression to predict the risk of exacerba-
tions using a threshold for entry into the model of p < 
0.05 and interactions between covariates were tested. The 
goodness of fit of the logistic regression model was 
confirmed by the Hosmer and Lemeshow test. A two- 
tailed significance level of 0.05 was used for all statistical 
procedures.
A sample size of at least 818 participants was needed for 
the multiple regression analysis based on a candidate set of 
10 independent variables, a small effect size (0.02 ƒ2) with 
80% power and a probability level of 0.05.
Results
Patient Cohort
There were 4274 adults aged ≥18 years with asthma in 
the iHARP database who had their asthma reviewed 
between June 2011 and December 2014 and all were 
included in the analysis. The study cohort included 2574 
(60.2%) from the UK, 652 (15.3%) from the 
Netherlands, 527 (12.3%) from Spain, 403 (9.4%) from 
Italy, 62 (1.5%) from Sweden, 36 (0.8%) from Norway 
and 20 (0.5%) from France. Table 1 shows patient 
characteristics: mean (SD) age of patients 50.9 (14.3) 
years; 60.8% female; 33.1% obese (body mass index 
≥30 kg/m2); 12.9% current smokers and 30.3% had 
GINA-defined controlled asthma.
Prevalence and Severity of Coexisting 
Rhinitis Symptoms and Treatment
Overall, 2881/4274 (67.4%) patients reported rhinitis 
symptoms; however, of those reporting rhinitis symp-
toms only 34.3% (987/2881) had a doctor diagnosis of 
rhinitis (Table 1), ie, 65.7% (1894/2881) of patients 
reporting rhinitis had not received a doctor diagnosis 
(Figure 1). Of patients reporting rhinitis symptoms, 
63.5% (1829/2881) were classified as having mild rhi-
nitis and 36.5% (1052/2881) having moderate-severe 
rhinitis. In the past year, 12.4% (358/2881) of 
patients indicated using intranasal corticosteroid 
(INCS) therapy for rhinitis and 19.8% (569/2881) oral 
antihistamines.
Characteristics of Patients Reporting 
Coexisting Rhinitis Symptoms
Patients reporting rhinitis symptoms were significantly 
more likely to be younger, female, have a normal body 
mass index and have a positive smoking history than those 
who did not (Table 1). The proportion of patients with 
GINA-defined uncontrolled asthma was significantly 
higher among those who reported rhinitis symptoms than 
those who did not (26.8% vs 21.0%, p <0.001) (Table 1); 
and even higher among patients with moderate-severe 
rhinitis than those with mild rhinitis (31.4% vs 24.2%, 
p <0.001) (Figure 2).
In the week before the review visit, a significantly 
higher proportion of patients who reported rhinitis symp-
toms experienced asthma symptoms for ≥3 days, had 
asthma symptoms affecting their sleep or had symptoms 
that interfered with daily activities than those who did not 
(Table 2). While there was no significant difference in 
frequency of SABA reliever use between the two groups, 
patients who reported rhinitis symptoms were signifi-
cantly more likely to have taken 5–12 puffs or more of 
SABA reliever on at least 1 day in the previous 4 weeks 
than those who did not (12.8% vs 9.5%, p=0.002) 
(Table 2). Furthermore, compared to patients who did 
not report rhinitis symptoms, those who did were more 
likely to have experienced exacerbations requiring short- 
term courses of oral steroids (38.8% vs 30.2%, p <0.001), 
have taken time off work/education (10% vs 16.6%, 
p<0.001) or visited the ED due to asthma (9.8% vs 
7.6%, p <0.001) in the 12 months prior the review visit 
(Table 2). Patients with GINA-defined partially con-
trolled/uncontrolled asthma who reported rhinitis were 
Kritikos et al                                                                                                                                                         Dovepress
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more likely to accurately perceived that their asthma was 
“not well controlled” than those with asthma alone 
(40.9% vs 32.7%, p<0.001).
Patients who reported rhinitis were significantly less 
likely to take preventer inhaler every day and to have 
had their inhaler technique reviewed by a HCP in the 
past year than those who did not (Table 3); yet they 
were significantly more likely to experience oropharyn-
geal effects while inhaling preventer treatment and side- 
effects from preventer asthma therapy symptoms than 
those who did not (Table 3). In addition, patients who 
reported rhinitis symptoms were significantly less likely 
to have seen a respiratory specialist for asthma in the 
past year (vs more than a year ago/never) than those 
who did not (Table 3).
Association of Rhinitis with Risk of 
Asthma Exacerbations
Results of exploratory analysis using univariable logistic 
regression identified moderate-severe rhinitis as one of the 
10 variables significantly associated with the risk of 
exacerbations (Table 4). All 10 variables were included 
in a multivariable logistic regression as there were no 
correlations between the univariate predictors. The multi-
variable logistic regression model was statistically signifi-
cant (χ2 = 122.61, df = 12, p< 0.001), accounting for 
16.9% (Nagelkerke R squared) of the overall variance. 
As reported in Table 5, moderate-severe rhinitis was sig-
nificantly associated with risk of asthma exacerbations 
(OR=1.40, 95% CI: 1.02–1.90). Other significant factors 
associated with exacerbation risk included: GINA-defined 
Table 1 Patient Demographics and Characteristics Overall and by Patient-Reported Rhinitis
Overall (N=4274) Patient-Reported Rhinitis p value*
No (n=1393) Yes (n=2881)
Age in years, mean (SD) 50.7 (14.3) 52.3 (14.0) 50.0 (14.4) <0.001a
Gender, n (%)
Female 2600 (60.8) 809 (58.1) 1791 (62.2) 0.01b
Male 1674 (39.2) 584 (41.9) 1090 (37.8)
BMI (kg/m2) category, n (%)
Underweight (BMI ≤18.49) 56 (1.3) 15 (1.1) 41 (1.4) 0.001b
Normal (BMI 18.5–24.99) 1293 (30.3) 371 (26.6) 922 (32.0)
Overweight (BMI 25–29.99) 1509 (35.3) 498 (35.8) 1011 (35.1)
Obese (BMI ≥30) 1416 (33.1) 509 (36.5) 907 (31.5)
Smoking history, n (%)
Never smoked 2364 (55.3) 808 (58.0) 1556 (54.0) 0.002b
Past smoker 1357 (31.8) 393 (28.2) 964 (33.5)
Current smoker 553 (12.9) 192 (13.8) 361 (12.5)
Comorbiditiesc, n (%), known (n=3622) (n=1273) (n=2385)
Rhinitis 1228 (33.9) 241 (19.5) 987 (41.4) <0.001b
Eczema 696 (19.2) 230 (18.6) 466 (19.5) 0.2b
GORD 480 (13.3) 150 (12.1) 330 (13.8) 0.1b
Asthma symptom control (GINA-defined)d, n (%)
Controlled 1296 (30.3) 442 (31.7) 854 (29.6) <0.001b
Partially controlled 1912 (44.7) 658 (47.3) 1254 (43.5)
Uncontrolled 1066 (25.0) 293 (21.0) 773 (26.9)
Perceived controle, n (%), known
Well controlled 2582 (60.4) 905 (65.0) 1677 (58.2) <0.001b
Not well controlled 1692 (39.6) 488 (35.0) 1204 (41.8)
Notes: p value* No rhinitis symptoms versus rhinitis symptoms. aP value from independent samples t-test. bP value from chi-square test for independence. cDoctor 
diagnosed comorbidities. dIn the 7 days before an iHARP asthma review. eIn the 4 weeks before an iHARP asthma review. 
Abbreviations: BMI, body mass index (kg/m2); GINA, Global Initiative for Asthma; GORD, gastroesophageal reflux disease; SD, standard deviation.
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uncontrolled asthma (OR=2.67, 95% CI: 1.76–4.04); not 
using preventer therapy every day (OR=1.96, 95% CI: 
1.27–3.03); oropharyngeal effects while inhaling preventer 
treatment (OR=1.93, 95% CI: 1.32–2.83); side-effects 
from preventer therapy (OR=1.82, 95% CI: 1.17–2.83); 
high-dose of SABA use (OR=1.83, 95% CI: 1.18–2.82); 
diagnosis of GORD (OR=1.83, 95% CI: 1.20–2.80); spe-
cialist review for asthma more than a year ago/never (vs 
previous year) (OR=1.77, 95% CI: 1.30–2.41) and obesity 
(OR=1.57, 95% CI: 1.16–2.12). Smoking status was not 
associated with risk of exacerbations. There were two 
significant interactions: between GINA-defined asthma 
control and oropharyngeal effects; and between preventer 
adherence and side-effects (Table 5). The risk of exacer-
bations among patients with controlled/partially controlled 
asthma increased if they experienced oropharyngeal 
effects, and similarly among preventer medication 
adherers if they experienced side-effects.
Discussion
This research using the data from a large cross-sectional 
observational study investigated patient-reported rhinitis 
and its association with risk of asthma exacerbations in a 
large cohort of adults with asthma treated at GINA Step 3 
Figure 1 Incidence of diagnosed and undiagnosed rhinitis among patients reporting rhinitis symptoms (N=2881).
Figure 2 Asthma symptom control status in patients with mild (N=1829) and moderate-severe rhinitis (N=1052).
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and above who are managed in primary care. Our study 
revealed: (1) the prevalence of patient-reported rhinitis 
was higher than that of doctor-diagnosed rhinitis, with 
undiagnosed and/or poorly managed rhinitis highly preva-
lent in this cohort; (2) asthma patients with moderate- 
severe rhinitis were more likely to have GINA-defined 
uncontrolled asthma than those with mild rhinitis or no 
rhinitis and (3) moderate-severe rhinitis is associated with 
40% increased risk of asthma exacerbations.
This cross-sectional observational analysis detected a 
major discrepancy between patient-reported and doctor- 
diagnosed rhinitis using data collected from the iHARP 
asthma review, which would have been difficult to detect 
via other approaches such as general practice databases or 
medical records used in other studies.18–26 Our results 
showed that concomitant rhinitis is highly prevalent in 
patients who are considered to have moderate-severe 
asthma; however, the fact that rhinitis is likely to be 
Table 2 Indicators of Asthma Symptoms and Exacerbations Overall and by Patient-Reported Rhinitis
Overall (N=4274) Patient-Reported Rhinitis p value*
No (n=1393) Yes (n=2881)
Asthma symptomsa
Daytime symptoms, n (%)
None 2045 (47.8) 772 (55.4) 1273 (44.2) <0.001b
1–2 days 956 (22.4) 284 (20.4) 672 (23.3)
≥3 days 1273 (29.8) 337 (24.2) 936 (32.5)
Activity limitations due to asthma, n (%)
None 3167 (74.1) 1109 (79.6) 2058 (71.4) <0.001b
≥1 day 1107 (25.9) 284 (20.4) 823 (28.6)
Night-time awakening, n (%)
None 3186 (74.5) 1150 (82.6) 2036 (70.7) <0.001b
≥1 day 1088 (25.5) 243 (17.4) 845 (29.3)
Reliever needed for symptoms, n (%)
None 2210 (51.7) 736 (52.8) 1474 (51.2) 0.6b
1–2 times 733 (17.2) 230 (16.5) 503 (17.5)
≥3 times 1331 (31.1) 427 (30.7) 904 (31.4)
Highest number of puffs of reliever inhaler taken in 1 daycd, n (%)
0–4 3773 (88.3) 1260 (90.5) 2513 (87.2) 0.002b
5–12 or more 501 (11.7) 133 (9.5) 368 (12.8)
Acute exacerbationse, n (%)
Oral steroid use for worsening asthma
None 2735 (64.0) 972 (69.8) 1763 (61.2) <0.001b
≥1 1539 (36.0) 421 (30.2) 1118 (38.8)
Emergency department visit due to asthma
None 3882 (90.9) 1286 (92.4) 2596 (90.2) <0.001b
≥1 visit 389 (9.1) 106 (7.6) 283 (9.8)
Hospitalisation due to asthma
None 4090 (95.7) 1335 (95.8) 2755 (95.7) 0.8b
≥1 stay 182 (4.3) 58 (4.2) 124 (4.3)
Days absent from work/education due to asthma (n=3617)
None 3099 (85.7) 1113 (90.0) 1986 (83.4%) <0.001b
≥1 day 5118 (14.3) 124 (10.0) 394 (16.6%)
Notes: p value* No rhinitis symptoms versus rhinitis symptoms. aIn the 7 days before an iHARP asthma review. bp value from chi-square test. cIn the 4 weeks before an 
iHARP asthma review. dHighest number of puffs of reliever inhaler use, in response to the question: “In the past 4 weeks, what was the highest number of puffs in 1 day you 
took of the reliever inhaler?” with response options 1–4 puffs, 5–12 puffs and >12 puffs. eIn the12 months before an iHARP asthma review.
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undiagnosed and/or poorly managed suggests that it may 
be more difficult for HCPs to diagnose rhinitis among 
patients with asthma, and/or is being overlooked by both 
patients and HCPs as a factor that can impair asthma 
control even with the most effective asthma therapy 
being prescribed.12,21,39,40,46 While asthma patients are 
known to underestimate the seriousness of their asthma,44 
our findings suggest that they also underestimate the sever-
ity of their coexisting rhinitis, with only 1 in 3 adults 
indicating symptoms of moderate-severe rhinitis, which 
is inconsistent with their asthma severity,10, and rates 
reported in previous studies.19,20,47 This research is novel 
as it for the first time, takes a real-world/pragmatic 
approach to understand the relationship between rhinitis 
and asthma. Research to date has almost exclusively eval-
uated the impact of having doctor diagnosed AR on 
asthma exacerbations.24,25 The current research focused 
on patient-reported rhinitis. Therefore, our study enables 
Table 3 Clinical and Behavioural Characteristics Overall and by Patient-Reported Rhinitis
Overall (N=4274) Patient-Reported Rhinitis p value*
No (n=1393) Yes (n=2881)
Patient-reported prior inhaler review by HCPa, n (%) 2221 (52.0) 791 (56.8) 1430 (49.7) 0.009b
Preventer adherence, n (%) (n=3761) (n=1264) (n=2497)
Take it every day 2081 (55.3) 805 (63.7) 1276 (51.0) <0.001b
Take it some days but others do not 994 (26.4) 261 (20.6) 733 (29.4)
Used to take it but now do not 235 (6.3) 66 (5.3) 169 (6.8)
Take it only when have symptoms 214 (5.7) 75 (5.9) 139 (5.6)
Never take it 237 (6.3) 57 (4.5) 180 (7.2)
Patient-reported side-effectsc, n (%)
≥1 1641 (38.4) 459 (33.0) 1182 (41.0) <0.001b
Patient-reported oropharyngeal effectsd, n (%) known (n=3755) (n=1264) (n=2491)
≥1 1833 (48.6) 472 (37.3) 1361 (54.6) <0.001b
Patient-reported specialist review, n (%)
Never 534 (12.5) 158 (11.3) 376 (13.1) 0.001b
More than a year ago 986 (23.1) 282 (20.2) 704 (24.4)
In the past year 2754 (64.4) 953 (68.4) 1801 (62.5)
Notes: p value* No rhinitis symptoms versus rhinitis symptoms. aIn the previous 12 months. bp value from chi-square test. cPatient-reported side-effects from preventer 
inhaler use, in response to the question: “Do you experience any of these side-effects from your preventer inhaler?” with “yes” or “no” responses for the following side- 
effects: continual sore mouth/throat; oral thrush; bruising; hoarse voice; abnormal weight gain and cough. Patients could indicate more than one side-effect. dPatient- 
reported oropharyngeal effects during the inspiration phase of preventer inhaler use, in response to the question: When you use your preventer inhaler, do you feel a 
sensation at the back of your throat?; do you sometimes feel a need to cough?; do you feel your medication is deposited at the back of your throat? With yes’ or “no” 
response options. Patients could indicate more than one oropharyngeal effect. In the 12 months before an iHARP asthma review. 
Abbreviation: HCP, healthcare professional.
Table 4 Univariable Associations Between Patient Characteristics and Risk of Asthma Exacerbations
Reference Category Category Odds Ratio (95% CI) p value
Body mass index Underweight/normal weight Obese 1.31 (1.13–1.53) 0.001
Gastroesophageal diagnosis No Yes 1.46 (1.19–1.79) < 0.001
Smoking status Never smoker Current smoker 1.74 (1.44–2.09) < 0.001
GINA-defined asthma symptom control Controlled/partially controlled Uncontrolled 1.40 (1.22–1.61) < 0.001
Rhinitis severity No Moderate-severe 1.74 (1.47–2.05) < 0.001
Preventer adherence Taken every day Not taken every day 2.42 (2.10–2.78) < 0.001
Highest number of puffs of reliever taken in 1 daya 0–4 5–12 or more 1.40 (1.16–1.69) < 0.001
Oropharyngeal effects during inspiration phase 0 ≥ 1 1.42 (1.23–1.64) < 0.001
Side-effects from preventer inhaler use 0 ≥ 1 0.62 (0.54–0.70) < 0.001
Respiratory specialist review In the previous year More than a year ago/never 0.71 (0.62–0.81) < 0.001
Note: aIn the 4 weeks before an iHARP asthma review. 
Abbreviation: GINA, Global Initiative for Asthma.
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us to identify potential confounding effects of undiagnosed 
or undocumented rhinitis in studies reporting on the 
impact of diagnosed rhinitis on asthma outcomes. This 
study uncovered the nature and extent of concomitant 
rhinitis in adults with asthma by using data collected via 
a structured asthma review approach, highlighting the need 
for such approaches to be an integral part of asthma con-
sultations in primary care.
Our study indicated that rhinitis has a negative impact 
on asthma symptom control. This finding confirms pre-
vious reports showing a negative effect of rhinitis on the 
level of asthma control assessed by the Asthma Control 
Questionnaire among adult asthma patients with a diagno-
sis of rhinitis or documented allergen sensitisation,18–20 
and that patients with moderate-severe rhinitis had the 
worst asthma control.17,48 In our study patients with rhini-
tis were less likely to use their preventer medication every 
day, yet were more likely to report side-effects from 
asthma therapy. While these findings seem contradictory, 
they may be explained by several factors: first, regular use 
of inhalers has shown to be associated with maintenance 
of correct inhaler technique (ie, practice makes perfect), 
thus irregular use of inhalers is associated with a deteriora-
tion in inhaler technique over time;49 second, patients 
reporting rhinitis in our study were less likely to have 
had their inhaler technique reviewed by a HCP in the 
past year – inhaler technique deteriorates over time and 
correct technique needs to be reinforced regularly, thus 
these patients are more likely to have poor inhaler 
technique;50 third, poor inhaler technique increases the 
risk of local side-effects such as dysphonia,51 and when 
side-effects occur, this reduces patient’s willingness to use 
their inhalers regularly, which in turn becomes a vicious 
cycle, and fourth, since the majority of patients with rhi-
nitis were not using optimal rhinitis therapy, our findings 
suggest that rhinitis with an inflamed mucosa might be a 
risk factor for local side-effects from preventer inhalers. 
This study also brings to light an interesting concept con-
cerning the patient’s ability to differentiate between coex-
isting upper and lower airway symptoms. Given that 
individually, worsening asthma symptoms and sympto-
matic episodes of rhinitis can cause night-time awaken-
ings, breathlessness and cough,12,33 and impact on the 
ability to undertake activities,7,52 these findings question 
whether asthma patients are able to distinguish between 
asthma symptoms, asthma and rhinitis symptoms or just 
rhinitis symptoms alone when they respond to GINA- 
defined criteria/questions that are being asked for an objec-
tive evaluation of asthma control. These findings identify a 
gap in the management of rhinitis in general practice and 
the need for practitioners to identify, evaluate and opti-
mally treat rhinitis in patients with asthma and better 
Table 5 Logistic Regression Predicting Likelihood of Asthma Exacerbations
Reference Category Category B Odds Ratio 
(95% CI)
p 
value
GINA-defined asthma symptom control Controlled/partially 
controlled
Uncontrolled 0.98 2.67 (1.76–4.04) <0.001
Preventer adherence Taken every day Not taken every day 0.67 1.96 (1.27–3.03) 0.002
Oropharyngeal effects during inspiration phase 0 ≥ 1 0.66 1.93 (1.32–2.83) 0.001
Gastroesophageal reflux disease No Yes 0.61 1.83 (1.20–2.79) 0.005
Highest number of puffs of reliever taken in 1 daya 0–4 5–12 or more 0.60 1.83 (1.18–2.82) 0.007
Side-effects from asthma therapy 0 ≥ 1 0.60 1.82 (1.17–2.83) 0.008
Respiratory specialist review In the previous year More than a year ago/ 
never
0.57 1.77 (1.30–2.41) <0.001
Body Mass Index Underweight/normal 
weight
Obese 0.45 1.57 (1.16–2.12) 0.003
Rhinitis severity No Moderate-severe 0.33 1.40 (1.02–1.90) 0.036
Smoking status Never smoker Current smoker 0.24 1.27 (0.89–1.83) 0.194
GINA-defined asthma symptom control*Oropharyngeal 
effects
Controlled/partially 
controlled
Uncontrolled −0.64 0.53 (0.29–0.97) 0.040
0 ≥ 1
Preventer adherence*Side-effects from asthma therapy Not taken every day Taken every day 0.59 1.80 (1.01–3.25) 0.049
≥ 1 0
Notes: *Interaction with. aIn the 4 weeks before an iHARP asthma review. 
Abbreviation: GINA, Global Initiative for Asthma.
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patient education concerning the link between rhinitis and 
asthma outcomes.
Interestingly, patients with suboptimal asthma control 
who reported rhinitis symptoms were more likely to accu-
rately perceive that their asthma was “not well controlled” 
than patients with asthma alone. This finding suggests that 
these patients are more likely to voice their concerns and 
report troublesome asthma symptoms, search for asthma- 
related information, education or care; this flags that while 
they recognise their asthma control is suboptimal, they may 
fail to recognise the coexistence of both chronic conditions,12 
are unaware of the link between asthma and rhinitis,37 under-
estimate the magnitude of the impact of rhinitis on their daily 
lives33,37,38 and often accept living with nasal symptoms,37,53 
and hence, do not complain or volunteer to provide informa-
tion about “trivial” nasal symptoms unless their physician 
asks.37,38 Primary care providers need to “prompt” patients 
by questioning them about the frequency, duration and 
impact of nasal symptoms on their daily lives when they 
are seeking asthma care. Our findings suggest the need to 
utilise simple validated assessment tools suitable for primary 
care, that capture both asthma and rhinitis symptom control, 
such as the Control of Allergic Rhinitis and Asthma Test 
(CARAT), which concurrently assesses symptoms of the 
upper and lower airways, sleep disturbances, limitation in 
normal activities and the need to adjust medication over a 
four-week period,54 or the MASK (Mobile Airways Sentinel 
Network)-air mobile phone application, which is specific for 
monitoring rhinitis in asthma and includes the CARAT.55
Importantly, this study found that moderate-severe rhi-
nitis is associated with 40% increased risk of exacerba-
tions among patients with asthma, despite GINA Step 3 
and above maintenance therapy being prescribed. This 
finding emphasises the need to ensure that rhinitis symp-
toms are optimally controlled in patients dually affected by 
asthma and rhinitis. Optimal treatment of the upper airway 
may improve lower airway-specific symptoms,56,57 reduce 
the need for rescue medication,23,56 improve rates of con-
trolled asthma and reduce future risk of adverse events.58 
The finding that current smoking was not linked to 
increased risk of exacerbations in our study is inconsistent 
with previous reports among patients seen in general 
practice.17 A possible explanation for current smoking 
not to be statistically significant in the multivariable 
regression model may be due to a lack of power as only 
12.9% of our patient cohort were current smokers. Two 
factors associated with exacerbation risk identified in our 
study, which have not been reported in the global strategy 
for asthma management,16 include side-effects of preven-
ter therapy and oropharyngeal effects while inhaling pre-
venter treatment. Risk of exacerbations doubled in patients 
experiencing side-effects and/or oropharyngeal effects 
from inhaled preventer medication; this risk increased 
even in patients with controlled/partially controlled asthma 
if they experienced oropharyngeal effects and in preventer 
medication adherers if they experienced side-effects. 
Oropharyngeal side-effects suggest poor inhaler technique 
which we know is related to poorer outcomes, such as 
poor asthma symptom control and increased risk of asthma 
exacerbations.51,59,60 Identification of the above three risk 
factors also suggests that these are potentially issues that 
could also be addressed by community pharmacy. 
Community pharmacists when dispensing asthma medica-
tion to people with asthma should check inhaler technique, 
adherence and oropharyngeal effects/side-effects of 
asthma medication, and recommend optimal rhinitis ther-
apy, which, in some countries is available over-the-counter 
without prescription.
The strengths of the study include its large-scale size, 
observational design, evidence from real-life clinical prac-
tice and utilisation of a structured face-to-face asthma 
review approach that included objective and patient- 
reported outcomes. Furthermore, this approach provided 
insight into patient behaviour such as inhaler technique 
that would have been difficult to capture via other 
approaches such as online surveys used in other studies. 
The study focused on those patients who had recent gen-
eral practice contact who were prescribed combination 
preventer therapy (ie, GINA Step 3 and above); this 
being the most commonly used maintenance therapy for 
asthma at the time in primary care. There are several 
potential limitations to this study, which are related to 
the cross-sectional study design and a reliance on patient 
recall for self-reported exacerbations and medication tak-
ing behaviour, particularly with oral steroid use for asthma 
that may have been under- or over-stated by patients, or 
the confounding effect of oral steroid use for other condi-
tions such as chronic rhinosinusitis. Other study limita-
tions relate to patient recruitment over several countries, 
which may have led to greater variability in responses and 
the exclusion of patients with mild asthma (treated at 
GINA Step 1 or 2). While there were criteria to exclude 
patients with a diagnosis of chronic obstructive pulmonary 
disease (COPD) and given that most patients were 
50 years of age or older with a past or current smoking 
history (and a greater risk of COPD), there is a possibility 
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that patients with both asthma and COPD were included 
and could have biased the results. It is likely that most 
rhinitis identified in this study was indeed allergic in 
origin, but this cannot be confirmed due to the absence 
of data relating to the sensitisation status of the study 
population. Finally, while significant risk factors were 
identified, the overall variance accounted by the multivari-
able logistic regression model was low, suggesting other 
clinical, attitudinal or behavioural characteristics not 
regarded in the current analyses may relate to exacerbation 
risk and the need for further research in this area.
Conclusion
This study identified a major gap in the diagnosis and manage-
ment of rhinitis in a cohort of people with asthma treated at 
GINA Step 3 and above who are managed in general practice. 
It highlights the need for practitioners to identify, evaluate and 
optimally treat rhinitis in adults with asthma, which is a sig-
nificant factor associated with exacerbation risk.
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